Selected article for: "high level and inflammatory disease"
Author: Arigondam, Ashok Kumar; Hakeem, Abdul Rahman; Reddy, Mettu Srinivas; Rela, Mohamed
Title: An evidence-based protocol for minimising thromboembolic events in SARS-CoV-2 infection
  • Cord-id: iw0s2yop
  • Document date: 2020_11_10
    • ID: iw0s2yop
    Snippet: Coronavirus Disease 2019 (COVID-19) is complicated by significant coagulopathy, that manifests in the form of both pulmonary artery microthromboses and systemic venous thromboembolism (VTE) leading to excess mortality. Dysregulated innate immune response in the lung due to viral-entry mediated angiotensin-I-converting enzyme 2 (ACE2) receptor downregulation causes endothelial injury in the pulmonary vasculature, inflammatory cytokine release, increased thrombin generation and impaired fibrinolys
    Document: Coronavirus Disease 2019 (COVID-19) is complicated by significant coagulopathy, that manifests in the form of both pulmonary artery microthromboses and systemic venous thromboembolism (VTE) leading to excess mortality. Dysregulated innate immune response in the lung due to viral-entry mediated angiotensin-I-converting enzyme 2 (ACE2) receptor downregulation causes endothelial injury in the pulmonary vasculature, inflammatory cytokine release, increased thrombin generation and impaired fibrinolysis. The inflammatory disease process, immobilization with prolonged hospital stay, hypoxia due to extensive lung injury and pre-existing comorbidities can contribute to thromboembolic episodes (TE). The observed risk for TE in COVID-19 is high despite anticoagulation, particularly in intensive care unit (ICU) patients. A high level of clinical suspicion, lower threshold for diagnostic imaging and aggressive early and extended thromboprophylaxis is indicated. The available evidence on the optimal strategies to prevent, diagnose, and treat VTE in patients with COVID-19 is heterogenous, but rapidly evolving. We propose an evidence-based, risk-stratified protocol in approaching the risk of TE episodes in COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • active bleeding and acute injury: 1, 2, 3
    • active bleeding and acute respiratory: 1, 2
    • active bleeding and lmwh weight heparin: 1, 2
    • active bleeding and low molecular: 1, 2, 3
    • active bleeding and low molecular lmwh weight heparin: 1, 2
    • acute inflammation and lmwh weight heparin: 1
    • acute inflammation and low molecular: 1, 2, 3
    • acute inflammation and low molecular lmwh weight heparin: 1
    • acute inflammation and lung protect: 1
    • acute injury and lmwh weight heparin: 1, 2, 3, 4
    • acute injury and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute injury and low molecular lmwh weight heparin: 1, 2, 3, 4
    • acute injury and lung protect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute pulmonary embolism and lmwh weight heparin: 1
    • acute pulmonary embolism and low molecular: 1, 2, 3, 4, 5, 6
    • acute pulmonary embolism and low molecular lmwh weight heparin: 1
    • acute respiratory and adequate fluid resuscitation: 1, 2, 3
    • acute respiratory and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25